The BARD1 C-Terminal Domain Structure and Interactions with Polyadenylation Factor CstF-50† by Edwards, Ross A. et al.
The BARD1 C-Terminal Domain Structure and Interactions with Polyadenylation
Factor CstF-50
†
Ross A. Edwards,
‡,§ Megan S. Lee,
‡,§ Susan E. Tsutakawa,
| R. Scott Williams,
⊥ John A. Tainer,
|,⊥ and
J. N. Mark Glover*
,§
Department of Biochemistry, UniVersity of Alberta, Edmonton, Alberta, Canada T6G 2H7, Life Sciences DiVision, Department
of Genome Stability, Lawrence Berkeley National Laboratory, Berkeley, California 94720, and Department of Molecular
Biology and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road,
MB4, La Jolla, California 92037
ReceiVed June 13, 2008; ReVised Manuscript ReceiVed August 20, 2008
ABSTRACT: The BARD1 N-terminal RING domain binds BRCA1 while the BARD1 C-terminal ankyrin
and tandem BRCT repeat domains bind CstF-50 to modulate mRNA processing and RNAP II stability in
response to DNA damage. Here we characterize the BARD1 structural biochemistry responsible for CstF-
50 binding. The crystal structure of the BARD1 BRCT domain uncovers a degenerate phosphopeptide
binding pocket lacking the key arginine required for phosphopeptide interactions in other BRCT proteins.
Small angle X-ray scattering together with limited proteolysis results indicates that ankyrin and BRCT
domains are linked by a ﬂexible tether and do not adopt a ﬁxed orientation relative to one another. Protein
pull-down experiments utilizing a series of puriﬁed BARD1 deletion mutants indicate that interactions
between the CstF-50 WD-40 domain and BARD1 involve the ankyrin-BRCT linker but do not require
ankyrin or BRCT domains. The structural plasticity imparted by the ANK-BRCT linker helps to explain
the regulated assembly of different protein BARD1 complexes with distinct functions in DNA damage
signaling including BARD1-dependent induction of apoptosis plus p53 stabilization and interactions.
BARD1 architecture and plasticity imparted by the ANK-BRCT linker are suitable to allow the BARD1
C-terminus to act as a hub with multiple binding sites to integrate diverse DNA damage signals directly
to RNA polymerase.
The breast and ovarian cancer associated protein, BRCA1,
together with its binding partner BARD1 (BRCA1-associated
RING domain protein 1), control the cell cycle in response
to DNA damage (1, 2). Both proteins interact through
N-terminal RING and adjacent helical domains to form a
heterodimeric E3 ubiquitin ligase that constitutes the major
catalytic activity of the BRCA1-BARD1 complex (3-5).
While the direct targets of BRCA1-BARD1 ubiquitination
are unclear, targeting likely involves conserved protein-protein
interaction domains in both BRCA1 and BARD1.
Critical protein-protein interactions are mediated by a pair
of sequence repeats at the C-terminus of BRCA1 called
BRCT repeats (for BRCA1 C-terminal repeats) (6, 7). Similar
repeats are found in a number of proteins involved in the
cellular response to DNA damage (8). In BRCA1, the BRCT
repeats mediate interactions with several proteins such as
BACH1/BRIP (9), CtIP (10, 11), and Abraxas (12, 13). In
each of these cases, the BRCA1 BRCT recognizes a
phosphopeptidemotifinthetargetprotein,pSer-x-x-Phe(14,15).
A series of structural studies have revealed that the N-
terminal BRCT repeat contains a pocket which recognizes
the phosphoserine, while the phenylalanine residue is rec-
ognized by an adjacent hydrophobic pocket formed at the
interface between the N- and C-terminal BRCT re-
peats (8, 16-20). Cancer-associated mutations have been
uncovered which speciﬁcally perturb the integrity of this
phosphopeptide binding surface, demonstrating the critical
importance of these interactions for the tumor suppression
function of BRCA1 (16, 21, 22).
BARD1 also contains tandem BRCT repeats at its C-
terminus, as well as a set of ankyrin repeats immediately
N-terminal to the BRCT region. In Vitro peptide binding
studies suggest the BARD1 BRCT repeats may bind serine-
phosphorylated peptides (23), although attempts to isolate
phosphorylation-dependent protein binding partners from
human cells for the BARD1 BRCT region have been
unsuccessful (24). Ankyrin repeats are also well-known
protein-protein interaction modules (25, 26), strongly sug-
gesting that this region could also function to recognize
targets of the BRCA1-BARD1 complex. Individual ankyrin
repeats consist of a helix-turn-helix followed by a  -hair-
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protrude from one face of the structure to constitute the
protein interaction surface. Both the ankyrin and BRCT
repeat regions of BARD1 have been demonstrated to be
required for chromosomal stability and homology-directed
repair of DNA damage in mammalian cells (27). A number
of missense variants within the BARD1 C-terminal regions
have been isolated from breast and ovarian cancer patients,
further highlighting the importance of this region for
BRCA1-BARD1 function (28-30).
A series of studies implicate the BARD1 C-terminus in
the regulation of mRNA 3′ processing in response to DNA
damage (31-34). DNA damage triggers interactions between
BRCA1-BARD1 and the CstF mRNA processing complex
at the sites of stalled transcription (32, 33). These interactions
may regulate the inhibition of transcription through the
targeted degradation of RNAP II (31), as well as the transient
inhibition of mRNA polyadenylation. Interactions between
the BRCA1-BARD1 heterodimer and the CstF complexes
depend on direct interaction of the BARD1 C-terminus and
the 50 kDa component of the CstF complex, CstF-50
(cleavage stimulation factor 50) (33).
Here we have probed the structures and CstF-50 binding
characteristics of BARD1 C-terminal regions. Limited pro-
teolysis reveals that the BARD1 ankyrin and BRCT repeats
constitute independent folded modules linked by a ﬂexible
tether. Small angle X-ray scattering (SAXS) indicates that
the ankyrin and BRCT repeats do not adopt a ﬁxed
orientation with respect to one another and imply that these
protein-protein interaction modules do not form a contigu-
ous rigid surface for interaction with binding partners.
Further, the crystal structure of the BARD1 BRCT repeat
uncovers a degenerate BARD1 BRCT phosphopeptide bind-
ing pocket with intact pSer interacting motifs but which lacks
binding determinants for the pSer + 3 hydrophobic speciﬁc-
ity pocket at the inter-BRCT repeat interface. Analysis of
the CstF-50 binding properties of a series of BARD1 deletion
mutants maps the principle CstF-50 interaction site to the
ankyrin-BRCT linker.
MATERIALS AND METHODS
Protein Expression and Puriﬁcation. Human BARD1
(423-777), BARD1 (423-553), and BARD1 (554-777)
were expressed as GST fusion proteins in Escherichia coli
strain BL21(DE3) and puriﬁed by glutathione afﬁnity chro-
matography. The BARD1 polypeptides were cleaved from
GST using PreScission protease (GE Healthcare Life Sci-
ences) and then puriﬁed from GST by anion-exchange
(BARD1 (423-553)) or cation-exchange chromatography
(BARD1 (423-777) and BARD1 (554-777)) followed by
gel ﬁltration chromatography.
Human CstF-50 (92-431) was expressed as a GST fusion
protein in E. coli strain BL21(DE3) and puriﬁed by glu-
tathione afﬁnity chromatography. Residues from 1 to 91 were
excluded from the construct to limit possible self-association
(35). The protein was then puriﬁed by anion-exchange
followed by gel ﬁltration chromatography.
Proteolytic Mapping of the BRCT Domain. Puriﬁed
BARD1 (423-777) at 2 mg/mL was digested with 5 µg/
mL trypsin for 0-60 min. The reaction was terminated with
phenylmethanesulfonyl ﬂuoride (PMSF), and the reaction
products were separated by SDS-PAGE and stained with
Coomassie blue. Electrospray mass spectrometry was used
to identify the masses of tryptic fragments.
Crystallization. Crystals of BARD1 BRCT (554-777)
crystal form I (CFI) were grown by vapor diffusion in
hanging drops at 4 °C by mixing 2 µL of 25 mg/mL BRCT
domain in protein solution (100 mM NaCl, 5 mM Tris-HCl,
pH 7.5, 1 mM dithiothreitol) with 2 µL of well solution (12%
PEG 8000, 0.1 M citrate, pH 3.9).
BARD1 BRCT crystal form II (CFII) was grown by vapor
diffusion in hanging drops at room temperature. The crystals
were grown by mixing 1 µL of 6 mg/mL BRCT domain
with a 1.5-fold molar excess of a Ac-pSDDE-NH2 peptide
in protein solution (100 mM NaCl, 5 mM Tris-HCl, pH 7.5,
1 mM dithiothreitol) with 1 µL of well solution (20% PEG
3350, 0.2 M ammonium chloride, pH 6.3). No evidence of
bound peptide was found in 2Fo - Fc or Fo - Fc electron
maps. For cryopreservation, single crystals were soaked in
the appropriate well solution supplemented with 26% (v/v)
glycerol and then ﬂash-frozen in liquid nitrogen.
Data Collection. All data were collected at beamline 8.3.1
of the Advanced Light Source, Lawrence Berkeley National
Laboratory, using an ADSC Q210 detector and a wavelength
of 11111 eV. Data were collected on CFI to 2.6 Å from a
single, elongated orthorhombic rod crystal. A total of 180°
of data were collected using5s1 ° oscillations at a crystal-
to-detector distance of 220 mm. The crystal was translated
twice at 60° and 120° to minimize radiation damage. Data
were indexed as primitive orthorhombic and scaled in the
space group P212121. The postreﬁned unit cell dimensions
were a ) 55.5 Å, b ) 67.9 Å, and c ) 120.4 Å, and the
mosaicity was 0.24°. Data were collected on CFII to 2.1 Å.
Crystals formed in the same space group as CFI but with a
different unit cell, a ) 56.8 Å, b ) 75.6 Å, and c ) 118.0
Å (see Table 1).
Structure Solution and Reﬁnement. A structure-based
sequence alignment was made from the superposition of
BRCT repeats from BRCA1 (PDB code 1JNX) and 53BP1
(PDB code 1KZY). The amino acid sequence of the BARD1
BRCT repeat was manually aligned to this structural align-
ment. Molecular replacement trial models were constructed
based on the main chain of the BRCT repeat from 1JNX
with side chains mutated to conform to the BARD1 sequence
based on the structural alignment. Extended loops and the
C-terminal extension were removed from the model. Using
this model a dyad search was preformed on data from CFI
in MOLREP (36), searching for two copies of the model
simultaneously. The rotation function was further constrained
to search only the rotations determined from a self-rotation
function, also calculated in MOLREP. A solution was found
having an initial R-factor and correlation coefﬁcient of 0.561
and 0.229, respectively. Rigid body reﬁnement in RE-
FMAC (37, 38) yielded an R-factor of 0.557 and R-free of
0.575. Rigid-body reﬁnement in CNS gave 0.551/0.545 for
R and R-free. Further simulated annealing reﬁnement with
torsion angle molecular dynamics in CNS (39) followed by
10 cycles of restrained reﬁnement on maximum likelihood
targets gave an R-factor of 0.425 and R-free of 0.469. The
model was further reﬁned in CNS to an R-factor of 0.335/
0.339 with NCS restraints imposed. The model was further
reﬁned against the 2.1 Å CFII data set in REFMAC utilizing
2-fold NCS restraints and TLS group anisotropic B-factor
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118 waters, and two glycerol molecules. The ﬁnal R-factor
and R-free were 0.223 and 0.262. We were unable to model
the N-terminal residues 554-568 in either chain nor residues
742-748 in chain A (part of the extended loop between  3′
and  4′ in the C-terminal BRCT domain), and we presume
these regions are disordered in the crystals. All model
building was carried out in COOT (40). An asymmetric 7σ
peak near His 686 in chain A could not be satisfactorily
modeled. The Ramachandran plot contained 92.8% of all
residues in the favored regions, and 99.7% of all residues
were in allowed regions (Table 1). Atomic coordinates and
structure factors have been submitted to Protein Database
(RCSB accession code 2R1Z).
GST Pull-down Assays. Fifteen micrograms of GST or
GST-CstF-50 (92-431) was incubated with 125 µgo ft h e
indicated BARD1 constructs for 30 min at 30 °Ci n2 5µL
ﬁnal volume wash buffer (400 mM NaCl, 20 mM Tris, pH
8.0, 1 mM EDTA, 0.5% NP-40, 1 µg/µL leupeptin, 0.7 µg/
µL pepstatin, and 25 µg/µL PMSF). Binding reactions were
incubated with glutathione-agarose beads for 90 min at 4
°C, and the beads were washed four times with the wash
buffer. Bound proteins were then eluted and separated by
SDS-PAGE and stained with SYPRO Orange (Sigma).
SAXS Data Collection. SAXS data were collected at
beamline 12.3.1 of the Advanced Light Source, Lawrence
Berkeley National Laboratory, at 12 keV on a MAR165
detector and used to analyze the solution architecture,
conformation, and assembly of BARD1 samples (41, 42).
Samples were maintained at 4 °C during data collection using
a thermostatically controlled cuvette. BARD1 (423-553) at
concentrations 3, 7, and 15 mg/mL and BARD1 (423-777)
at concentrations 2.5, 5, and 10 mg/mL were buffer-
exchanged overnight at 4 °Ci n5 0µL dialysis buttons,
utilizing 6-8 kDa nominal MWCO regenerated cellulose
dialysis tubing, against a 50 mL volume of the SAXS buffer
(100 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1 mM dithio-
threitol). The dialyzed samples were separated into two equal
volumes with half the sample being exposed as is and the
remainder passed through a 0.1 µm spin ﬁlter (Millipore
Ultrafree-MC Durapore PVDF 0.5 mL) immediately prior
to measurement. A series of exposures (either 6, 60, and 6 s
or 6, 6, 60, and 6 s) were measured to assess for radiation
sensitivity. Scattering of the dialysis medium alone from 6
or 60 s exposures was subtracted from the scattering of the
equivalently exposed samples to yield scattering curves for
the macromolecules alone. Data were analyzed using the
programs PRIMUS (43), GNOM (44), AUTOGNOM, and
AUTORG (45).
BARD1 (423-777) at 2.5 mg/mL yielded data that were
too noisy for further analysis, even at the longer exposure
time. At 10 mg/mL, in both ﬁltered and nonﬁltered samples,
radiation sensitivity was apparent, leading to curves that
tended to higher intensity at low s (s < 0.05 Å-1) with
increasing X-ray exposure. Radiation sensitivity appeared
attenuated at 5 mg/mL in the nonﬁltered sample relative to
that seen at 10 mg/mL, and in the 0.1 µm ﬁltered sample
was not apparent with the scattering curves of the ﬁrst and
last exposures overlaying within the noise limits of the data.
In general, scattering curves of the ﬁltered samples were
more consistent, particularly at high s (s > 0.20 Å-1), than
their nonﬁltered counterparts. Scattering curves of the ﬁltered
samples from the initial short 6 s exposure at all three
concentrations were scaled and compared to detect possible
concentration-dependent oligomerization or aggregation. All
three curves superimpose at low s with only slight deviation
visible in the 10 mg/mL sample, indicating the ﬁltered
samples are inherently monodisperse at 2.5 and 5 mg/mL.
To further test for aggregation, plots of log(I(s)) vs s2
(Guinier plots) were used to obtain estimates of the radius
of gyration (RG) using the program AUTORG. As only small
amounts of aggregate are needed to contribute signiﬁcantly
to scattering at low s, a linear dependence of log(I(s)) vs s2
in the range sRG < 1.3 indicates an absence of aggregation.
The increase of RG with accumulated exposure time at 10
mg/mL, from 32.8 Å after 2 s exposure to 39.4 Å after 82 s,
clearly shows the radiation-induced aggregation that occurs
at this concentration. At 5 mg/mL this trend is not observed
(RG 32.3 Å after 6 s and 29.4 Å after 78 s). RG after 6, 6,
and 4 s exposure for 2.5, 5, and 10 mg/mL, respectively,
are 31.4, 32.3, and 35.2 Å. The scattering curve from the
ﬁltered sample at 5 mg/mL, 60 s exposure, was chosen as a
BARD1 (423-777) representative curve for further analysis
due to its combination of low noise and monodispersity
(Figure 2A,C). Multiangle laser light scattering (MALLS)
performed at room temperature in the same buffer determined
BARD1 (423-777) to be monomeric at 4 mg/mL (see
Supporting Information, Figure S1). The RG for the selected
BARD1 (423-777) scattering curve as calculated by AU-
TORG (Figure 2C) was 33.2 ( 0.05 Å using data points
10-45 (0.0155 to 0.0368 Å-1), consistent with that calculated
independently using GNOM, RG ) 33.1 Å, at Dmax 100 Å.
The ﬁrst 10 data points were removed for all subsequent
analysis due to high associated error (mean percentage error
of 5.2% for points 1-10 compared with 1.2% for points
Table 1: Crystallographic Data Collection, Phasing, and Reﬁnement
Statistics
CFI CFII
space group P212121 P212121
cell dimensions
a (Å) 55.48 56.82
b (Å) 67.91 75.55
c (Å) 120.40 117.97
cell angles (deg)
wavelength (Å) 1.1159 1.1159
resolution range (Å) 50-2.6 (2.69-2.60) 28.4-2.1 (2.18-2.10)
observations 200053 231155
unique reﬂections 13944 28825
completeness (%) 95.3 (68.2) 94.9 (70.0)
〈I/σI〉 31.5 (2.8) 35.5 (2.2)
linear R-factor 0.052 (0.282) 0.032 (0.437)
resolution range (Å) 28.4-2.1
R-factor/R-free 0.223/0.262
no. of reﬁned atoms
protein 3312
water 118
other 12
rms deviations
bonds (Å) 0.010
angles (deg) 1.221
average B-factors (Å2)
main chain 46.6
side chain and waters 47.2
all atoms 46.9
Ramachandran
most favored 333 (92.8%)
allowed 24 (6.7%)
generously allowed 1 (0.3%)
disallowed 1 (0.3%)
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range 0.016 < s < 0.325 Å-1.
BARD1 (423-553) data were treated similarly. AUTORG
calculated RG as 16.2 Å using data points 28-101. The ﬁrst
27 data points were subsequently discarded and data used
in the range 0.030 < s < 0.346 Å-1.
Estimation of Dmax. The programs GNOM and AUTOG-
NOM were used to estimate Dmax, the longest intraatomic
vector in the solution structure. AUTOGNOM calculated
Dmax and RG for BARD1 (423-777) as 99.6 and 32.9 Å,
respectively. Further, GNOM was used to evaluate the p(r)
function in the range 50 < Dmax < 150 Å spanning the value
initially determined by AUTOGNOM. A clear maximum for
the Q-score, an overall score used to judge the quality of
the solution, was obtained at Dmax 105 Å, consistent with
the value obtained from AUTOGNOM. Visual inspection
of plotted p(r) curves revealed, however, that while the p(r)
function generally tended to p(r) ) 0 at approximately 105
Å, a tail-off of the p(r) function could be observed out to
Dmax ∼ 120 Å. The radius of gyration of BARD1 (423-553)
calculated from the Guinier plot using PRIMUS was 16.5 Å
for data with sRG < 1.3 (Figure 2C). The ﬁrst 28 data points
were excluded. RG and Dmax calculated using GNOM were
16.7 and 50 Å, respectively, with a Q-score of 0.942. Similar
results were obtained using AUTORG and AUTOGNOM
with RG and Dmax of 16.2 and 49 Å, respectively.
SAXS Structure Determination. Ab initio molecular enve-
lopes for the ankyrin repeat domain were calculated using
the programs DAMMIN (46) and GASBOR (47). In the later
case, intensities were ﬁt in reciprocal space. The programs
were repeated 20-40 times with the same input parameters
but a different, randomly chosen, value to seed the molecular
dynamics calculation. Envelopes from these independent
iterations were superimposed, averaged, and ﬁltered using
the programs SUPCOMB (48) and DAMAVER (49). A
structural model for the ankyrin repeat in BARD1 was
created using the 3D-JIGSAW (version 2.0) server (http://
www.bmm.icnet.uk/servers/3djigsaw) in automated mode,
which builds three-dimensional models for proteins based
on homologues of known structure (50-52). The structural
homologue used by 3D-JIGSAW as the basis for the model
was gankyrin, containing seven ankyrin repeats (PDB ID
1UOH).
The multidomain ankyrin-BRCT construct was tested for
interdomain ﬂexibility using the ensemble optimization
method (EOM) (53). A pool of 10000 models, treating each
domain as a rigid body connected by a ﬂexible linker, was
randomly generated using the program RANCH. The pool
effectively sampled the possible conformational space of the
ankyrin-BRCT structure. A genetic algorithm, implemented
in the program GAJOE, was then used to select a subset
(ensemble) of models from the pool ﬁtting best to the
experimental data. The distribution of two criteria, RG and
Dmax, was used to quantitatively compare the optimized
ensemble against the pool. The ﬁnal optimized ensemble
consisted of 19 models had a mean RG and Dmax of 30.5 and
95.1 Å, with a range of 12.2 and 38.5 Å, respectively. The
mean RG and Dmax of the pool were 31.8 and 100.7 Å, with
a range of 25.4 and 87.6 Å, respectively.
RESULTS
Mapping Structural Domains within the BARD1 C-
Terminal Region. Sequence analysis of BARD1 C-terminal
to the RING domain suggested the presence of three to four
ankyrin repeats followed by a pair of tandem BRCT repeats.
To better understand BARD1 domain architecture, we ﬁrst
employed limited proteolytic mapping to locate folded
protein domains within a puriﬁed C-terminal fragment of
human BARD1 (423-777) which contains both the ankyrin
and BRCT repeat domains. Tryptic digestion rapidly con-
verted BARD1 (423-777) into two protease stable fragments
(Figure 1). Electrospray mass spectrometry and N-terminal
sequencing of the large trypsin fragment identiﬁed a protein
with molecular mass 25736 ( 5 Da and an N-terminal
alanine, corresponding to BARD1 residues 554-777. This
fragment contains both BARD1 BRCT repeats, indicating
that the two BRCT repeats form a stable structural unit
similar to those of BRCA1 and MDC1 (20, 54). Mass
spectrometry of the small fragment revealed a mass of 14301
( 1 Da matching the BARD1 ankyrin repeat region spanning
residues 423-553. This analysis shows that the ankyrin
repeat regions and the tandem BRCT repeats each adopt
stably folded structures linked by a protease-sensitive linker
peptide.
X-ray Crystal Structure of the BARD1 BRCT Repeats. To
probe the structure of the BARD1 C-terminus, we crystallized
and determined the X-ray structure of the tandem BARD1
BRCT repeat domain (554-777). The BARD1 BRCT repeat
structure was solved using molecular replacement methods
and reﬁned to 2.1 Å resolution (see Materials and Methods).
The structure of BARD1 (554-777) is reminiscent of the
BRCT repeats in BRCA1 and MDC1 with the two BRCT
domains packing in the same head-to-tail manner (Figure
3A). The structure determined here is also essentially
identical to the structure of a smaller BARD1 BRCT
fragment recently determined by Birrane et al. (55).
The N-terminal domains of BRCT repeats whose structures
are known are structurally well conserved relative to their
C-terminal BRCT domains, which tend to have larger and
more diverse loops. A major difference in the N-terminal
BRCT domain of BARD1 occurs in the loop between helix
R3 and the linker helix. In both BRCA1 and MDC1, a 10-13
amino acid variable loop caps the N-terminal end of the
linker helix. This loop is absent in BARD1. Residues in this
FIGURE 1: The BARD1 ankyrin and BRCT repeats are tethered by
a ﬂexible linker. BARD1 (423-777) was digested with trypsin for
the times indicated, and the products were analyzed by SDS-PAGE.
The open arrow indicates the BARD1-BRCT fragment, and the
closed arrow indicates the BARD1-ankyrin fragment.
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phenylalanine binding sites. Likewise, the topology and core
of the C-terminal domain are conserved. However, the loop
connecting  2′ and  3′ is signiﬁcantly longer in BARD1
covering the base of the C-terminal domain core, distal to
the peptide binding face.
An amino acid sequence comparison of BARD1 with
BRCA1 and MDC1 revealed that the residues involved in
directly binding to the phosphoserine in the N-terminal
BRCT domain are conserved in BARD1 (Ser1655, Gly1656,
Thr1700, and Lys1702) and functionally conserved in MDC1
(Thr1898, Gly1899, Thr1934, and Lys1936) (16). Superposi-
tion of the BARD1 BRCT structure on that of BRCA1 and
MDC1 further shows that the arrangement of these residues
are spatially conserved, consistent with the hypothesis that
this surface may also act as a phosphate binding site in
BARD1 (Figure 3B). Indeed, a previous peptide selection
study suggested that the tandem BARD1 BRCT repeats
preferred phosphoserine-containing peptides (15).
In contrast to the phosphoserine recognition motifs, the
pSer + 3 speciﬁcity pocket of BARD1 is quite different from
that of BRCA1 (16) and MDC1 (20, 56). Arg1699, one of
the critical phosphopeptide recognition residues in this region
of BRCA1, hydrogen bonds to the main chain of the +3
residue peptide targets and orients the phenylalanine side
chain to dock into the +3 speciﬁcity pocket (16). A cancer-
associated missense mutation of this residue (R1699W) in
FIGURE 2: SAXS analysis of the C-terminal region of BARD1. (A)
Top curve set: Experimental SAXS curve of the ankyrin-BRCT
(BARD1 (423-777), black crosses); best ﬁt of the optimized
ensemble to the data (red line),   ) 2.2. Bottom curve set:
Experimental SAXS curve of the ankyrin repeat (BARD1 (423-553),
black crosses); theoretical scattering curve calculated by CRYSOL
of the 3D-jigsaw ankyrin model (blue line); best ﬁt of a single
GASBOR ankyrin model (red line),   ) 2.2. (B) Distance
distribution function, p(r), calculated using GNOM. The p(r)
function of ankyrin is a bell-shaped curve representative of a
compact globular protein. The ankyrin-BRCT p(r) function repre-
sents a more elongated structure, tailing off beyond 100 Å. For
comparison, the calculated p(r) function of a hypothetical compact
model generated by the EOM is shown in red. (C) Guinier plots
for BARD1 (423-553) (crosses) and BARD1 (423-777) (dots)
with line of best ﬁt. Inset: Kratky plots of BARD1 (423-553) (solid
line) and BARD1 (423-777) (double-solid line).
FIGURE 3: Structure of the tandem BRCT repeats of BARD1. (A)
Overview of the BARD1 BRCT structure (orange) aligned with
the structure of the BRCA1 BRCT (blue) bound to an optimized
phosphopeptide target (green) (PDB accession code 1T2V). (B)
Details of the phosphopeptide recognition surfaces of BRCA1 and
BARD1, colored as in (A). Residues involved in peptide binding
are labeled and shown as sticks.
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binding (16), underscoring the importance of this residue in
mediating phosphopeptide interactions in the BRCT protein
family. In MDC1, the corresponding residue, Arg1933,
adopts a similar conformation to Arg1699 in BRCA1 (20).
This arginine forms a strong, dual salt-bridging interaction
with the negatively charged carboxyl terminus of its interact-
ing peptide, γ-H2AX (56). Interestingly, BARD1 contains
a serine instead of an arginine in the +3 speciﬁcity pocket,
suggesting that interactions with the peptide main chain at
+3 may be very different from that of BRCA1 or MDC1.
Oriented peptide library analysis indicated that the BARD1
BRCT repeat speciﬁcally recognizes pS-[D/E]-[D/E]-E (23).
To probe the afﬁnity of the BRCT domain of BARD1 for
the predicted peptide substrates, we monitored the change
of BARD1 intrinsic ﬂuorescence upon binding to peptide
substrates. Binding afﬁnities were measured for the phos-
phopeptide (ﬂuorescein-pSDDE-CONH2) as well as for the
nonphosphorylated counterpart (ﬂuorescein-SDDE-CONH2).
BARD1 failed to show any binding to either peptide in these
studies, while binding was demonstrated between the BRCA1
BRCT domain and its phosphopeptide target from BACH1
(ﬂuorescein-GGSRSTpSPTFNK-CONH2) (data not shown).
The interaction may be transient during DNA damage repair,
suggested by the low BARD1-BRCT speciﬁcities for the
phosphopeptide residues at positions from 0 to +3( 23).
A previous report has suggested that Thr714 and Thr734
in BARD1 may be important DNA damage phosphorylation
sites (57). Our structure shows that Thr734 is buried within
a BRCT repeat whereas Thr714 is exposed to solvent.
Therefore, it is unlikely that Thr734 is a true phosphorylation
site, possibly explaining why phospho-speciﬁc antibody
raised against pThr734 peptide failed to recognize BARD1
(57). Inhibition of 3′ mRNA cleavage after DNA damage
and preferential degradation of RNAP IIO in BARD1 T734A
mutant may be due to its negative effects on integrity of the
BRCT repeat structure. In contrast, Thr714 is positioned
within a large loop on the surface of the C-terminal BRCT
repeat between R1′ and  2′.
Probing the Solution Structure of the BARD1 C-Terminal
Domain by Small Angle X-ray Scattering. We were unable
to crystallize the BARD1 ankyrin-BRCT region (BARD1
(423-777)), suggesting the ankyrin-BRCT linker imparts
ﬂexibility to the protein that hinders crystallization. Consis-
tent with this observation and our proteolysis results (Figure
1), residues 554-568 are completely disordered in both
chains in the crystallographic asymmetric unit of our
BARD1-BRCT structure. We therefore propose that residues
554-568 belong to a ﬂexible linker that connects the ankyrin
and the BRCT domains. To further understand the structural
nature of the ankryin-BRCT assembly, we employed solution
small angle X-ray scattering (SAXS) to study structures of
the BARD1 ankyrin repeat and ankyrin-BRCT assemblies.
SAXS Analysis of the BARD1 Ankyrin Repeats. The
distance distribution function calculated from the X-ray
solution scattering of the BARD1 ankyrin repeat region
(423-553) shows an asymmetric bell-shaped curve with a
peak at r ∼ 18 Å and slightly skewed toward higher r (Figure
2B). Such a curve is typical of a moderately asymmetric but
globular protein. An inﬂection point leading to a tail-off in
the curve can be observed at ∼35 Å, perhaps indicating the
presence of a second, partially distinct, structural entity. A
Kratky plot, while showing a distinct bell-shaped curve,
plateaus at I(s)s-2 > 0 (Figure 2C, inset), an indicator that
this construct may be partially unfolded in solution (58, 59).
Sequence analysis of the ankyrin domain indicates three
ankyrin repeats spanning residues 427-525. A possible
fourth repeat having poor sequence similarity can be manu-
ally assigned to residues 526-548 with the C-terminal loop
of the fourth repeat being part of the 20 amino acid linker
549-568. To determine the number of ankyrin repeats in
the minimum fragment, BARD1 (423-553) and BARD1
(423-526), which correspond to four and three ankyrin
repeats, respectively, were expressed in BL21(DE3). BARD1
(423-526) showed a very low level of expression (data not
shown), suggesting that the minimum fragment is most
consistent with the domain containing four ankyrin repeats.
Further conﬁrmation that BARD1 (423-526) contains four
and not three ankyrin repeats comes from a comparison of
the maximum dimension of this domain (Dmax) determined
from the SAXS data compared with the maximum dimen-
sions of ankyrin repeat structures determined by X-ray
crystallography. The SAXS data yields a Dmax of 50 Å for
BARD1 (423-553), consistent with Dmax of 49-52 Å for
four repeat ankyrin structures (PDB ID 1DCQ, 1N0R, 1S70,
1YCS) and signiﬁcantly larger than the Dmax of 40 Å for a
three repeat ankyrin structure (PDB ID 1N0Q).
Next, the ab initio modeling program GASBOR was used
to generate models minimizing the ﬁt to the experimental
SAXS data in reciprocal space. Multiple iterations of the
program were run and the resulting models averaged to give
ﬁnal models that ﬁt the data with average  2 values of 1.6
(see Materials and Methods and Figure 4). The overall shape
of the ankyrin domain is cylindrical with a small constriction
approximately two-thirds of the way along its 50 Å length
(Figure 4). Using SITUS (60), the X-ray crystal structure of
a three-repeat designed consensus ankyrin domain (61), PDB
ID 1N0Q, was automatically docked into the SAXS enve-
lope. The three ankyrin repeats ﬁt neatly into the larger
cylindrical portion of the envelope. Due to the narrowing of
the envelope at the end the potential fourth C-terminal repeat
cannot be accommodated if structured as a standard ankyrin
motif. Secondary structure prediction (JPRED, data not
shown) suggests a helix-turn-helix motif for the fourth
repeat. The fourth repeat therefore likely forms in a
nonstandard orientation or is only partially folded. The
remaining six to eight amino acids in BARD1 (423-553),
which form the beginning of the 20 amino acid linker to the
BRCT domain, may be entirely unstructured. While this
paper was in preparation, a crystal structure of the ankyrin
repeat region of BARD1 was reported. This structure
demonstrates that BARD1 contains four ankyrin repeats, with
a slightly truncated fourth repeat (62). The rms difference
between all main chain atoms of the homology model and
crystal structure is 2.0 Å. This structure was also docked
into the GASBOR envelop of the ANK domain (Figure 4C)
and gives a satisfactory ﬁt to the experimental data ( 2 values
of 4). Additional density is seen in the GASBOR envelop
which likely corresponds to the unstructured residues 546-553
present in both the crystallized fragment and the fragment
used in the SAXS analysis.
SAXS Analysis of the BARD1 Ankyrin-BRCT Domain. To
probe the solution structure and interdomain dynamics of
the intact BARD1 C-terminal domain, we next carried out
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of BARD1 (423-777). Guinier plots for data with sRG <
1.3 showed a good ﬁt to linearity, indicating the sample was
not aggregated (Figure 2C). Both the scattering curve and
the distance distribution function, p(r), exhibited features
broadly characteristic of an elongated molecule as described
in ref63. The scattering curve is rather featureless and decays
slowly. The p(r) function has a maximum at small r, which
corresponds approximately to the radius of the cross section,
before decreasing linearly to p(r) ) 0 at the maximum
dimension of the particle (Dmax) (Figure 2B). Two additional
features in the p(r) function are observed: a shoulder at r ∼
40 Å and tailing-off of the p(r) function at r > 90 Å. The
shoulder in the p(r) function suggests the presence of a
second, partially distinct, structural domain in the molecule.
The observed tailing-off of the p(r) function suggests the
possible presence in solution of conformational heterogeneity
leading to a broader range of Dmax. However, the Kratky
plot was consistent with that of a folded protein, having a
bell-shaped curve that does not plateau at higher s-values
(Figure 2C, inset).
Given that the C-terminal region is a multidomain protein
joined by a proteolytically labile linker and that conforma-
tional heterogeneity was suggested from analysis of the p(r)
function, the solution scattering proﬁle was ﬁrst tested for
interdomain ﬂexibility using the ensemble optimization
method (53). An ensemble, optimized against the experi-
mental SAXS curve using a genetic algorithm, was selected
from a pool of 10000 randomly generated C-terminal domain
conformers. Values of RG and Dmax for the ensemble were
compared against those calculated from the pool. In the case
where the molecule adopts a limited set of conformations in
solution, the ensemble is expected to sample a narrow range
of RG and Dmax relative to the values in the pool. However,
if the molecule is ﬂexible, sampling a large number of
interdomain conformations in solution, the distribution of
RG and Dmax values will be correspondingly broad, more
comparable to those of the pool (53, 64). The C-terminal
domain of BARD1 resembles the later case and thus exhibits
conformational heterogeneity in solution via its ﬂexible linker
(Figure 5A,B). All models in the optimized ensemble are
shown aligned on their BRCT domains in Figure 5C. The
theoretical scattering curve of the ensemble ﬁts that of the
experimental scattering curve with a  2 ) 2.2 (Figure 2A).
For comparison, the calculated p(r) function of the most
compact model generated by the EOM (RG ) 20.5 Å, Dmax
) 69.4 Å,   ) 13) has a single peak and no extended tail
(Figure 2B).
The BARD1 Ankyrin-BRCT Linker Is Critical for Interac-
tions with CstF-50. To probe the functional role of BARD1
C-terminal domain ﬂexibility in interactions with its protein
partners, we mapped the regions of BARD1 required for
physical interactions with CstF-50. CstF-50 (92-431), lack-
ing the 91 amino acid tail N-terminal to its WD-40 domain,
was previously shown to be necessary and sufﬁcient for
BARD1 interactions by two-hybrid studies (33). To conﬁrm
this interaction, GST-CstF-50 (92-431) and BARD1
(423-777) were puriﬁed separately from E. coli and used
in GST pull-down assays (Figure 6A). BARD1 (423-777)
bound to GST-CstF-50 (92-431), but not to GST alone,
revealing a speciﬁc interaction between the two proteins. To
map the region of BARD1 required for interaction with CstF-
50, we compared binding of CstF-50 to the isolated ankyrin
domain (BARD1 (423-553)), the linker-BRCT construct
(BARD1 (554-777)), the BRCT repeat alone (BARD1
(569-777)), and the ankyrin-linker-BRCT construct (BARD1
(423-777)). The isolated BRCT repeat exhibited weak CstF-
50 binding, and the ankyrin domain in isolation did not bind
to CstF-50, suggesting these regions make minimal contribu-
tions to high-afﬁnity CstF-50 interactions (Figure 6C). In
contrast, the ANK-linker-BRCT and linker-BRCT displayed
robust CstF-50 binding (Figure 6A,B), implicating the
ﬂexible ankyrin-BRCT linker as the core CstF-50 interaction
region.
DISCUSSION
Functionally important conformational ﬂexibility in the
interactions with multiple protein partners has recently been
characterized as critical in proteins that act as hubs for the
integration of information for DNA repair and DNA replica-
tion pathways (65, 66). Here we ﬁnd that BARD1, which
acts in the control of the cell cycle in response to DNA
damage (1, 2), unexpectedly employs a ﬂexible linker region
FIGURE 4: SAXS envelope for the BARD1 ankyrin domain. (A) The DAMAVER reference bead model of BARD1 (423-553) (spheres),
a single GASBOR iteration, superimposed on the averaged and ﬁltered envelope (gray mesh) from multiple GASBOR iterations. (B) Three
repeat ankyrin domain (PDB ID 1N0Q) docked using SITUS into the GASBOR envelope of BARD1 (423-553). (C) Superposition of the
ankyrin homology model (blue) and crystal structure (red) with both docked manually into the BARD1 (423-553) GASBOR envelope
(gray semitransparent surface). The rms difference between all main chain atoms of the homology model and crystal structures is 2.0 Å.
The fourth repeat of this standard ankyrin domain makes a poor ﬁt to the GASBOR envelope, suggesting the C-terminal fourth repeat of
BARD1 (423-553) may be in an atypical conformation in solution. The ﬂexible linker residues 546-553 were not modeled in either the
crystal structure or the 3D-jigsaw ankyrin model.
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BARD1&#x2bc;s structure may facilitate its ability to act
as a hub for multiple partners and thereby provide a means
to integrate information for control of transcription and
RNAP II in response to DNA damage.
Our biochemical, crystallographic, and small angle X-ray
scattering data characterize the structural biochemistry for
BARD1 interactions with CstF-50. The combined results
indicate that the C-terminal region of BARD1 consists of a
two-domain structure connected by a ﬂexible peptide linker.
SAXS data show that the solution structure is most consistent
with an ensemble of ankyrin-BRCT models suggesting that
the two domains sample a wide range of orientations with
respect to one another (Figure 5C), reminiscent of those seen
for mismatch repair interactions (66). In addition, a recent
NMR spectroscopic study failed to uncover any interactions
between the BARD1 ankyrin and BRCT domains (62). Thus,
the protein interaction surfaces on the ankyrin and BRCT
domains are not prealigned to form a contiguous recognition
surface as might be expected but instead provide a means to
alter BARD1 architecture depending upon its partner interac-
tions with the linker region.
CstF-50 is the best characterized binding partner for the
BARD1 C-terminal region. Our pull-down data demonstrate
that speciﬁc interactions between the CstF-50 WD-40 domain
and BARD1 critically depend on the BARD1 interdomain
FIGURE 5: BARD1 ankyrin-BRCT fragment samples a broad range
of conformations in solution. Frequency of occurrence of RG (A)
and Dmax (B) values for the optimized ensemble (empty boxes)
compared to those of the pool of 10000 randomly generated
conformations (ﬁlled boxes). The optimized ensemble, representing
the BARD1 C-terminal domain in solution, samples a broad range
of both RG and Dmax, comparable to those of the pool. The
C-terminal domain of BARD1 is therefore described as conforma-
tionally ﬂexible in solution. The RG and Dmax ranges are however
both systematically shorter than for those in the pool. This may be
due to a partially folded rather than completely ﬂexible linker. (C)
The conformational ﬂexibility of the BARD1 C-terminal domain
in solution is shown by the optimized ensemble that best represents
the experimental SAXS curve. The 19 models within the ensemble
were aligned on their BRCT domains. The BRCT repeat is shown
in red, the ﬂexible linker is in blue, and ankyrin domains are in
gray.
FIGURE 6: The BARD1 ankyrin-BRCT linker is critical for
interactions with CstF-50. (A) Interaction of GST-CstF50 (92-431)
and BARD1 (423-777). The BARD1 construct containing both
ankyrin repeats and BRCT repeats was incubated with puriﬁed GST
or GST-CstF50 (92-431). Bound proteins were eluted and resolved
by SDS-PAGE. Five percent of the GST-CstF50 (92-431) used
in binding reactions is shown. (B) Requirement of the BARD1
linker for CstF-50 interaction. BARD1-BRCT derivatives with or
without the BARD1 linker were used in binding reactions with
GST-CstF50 (92-431). Five percent of each of the GST-CstF50
(92-431) used in binding reactions is shown. (C) Lack of
interaction between BARD1-ankyrin and GST-CstF50 (92-431).
BARD1-ankyrin was incubated with puriﬁed GST or GST-CstF50
(92-431). Five percent of the BARD1-ankyrin used in binding
reactions is shown.
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protein complexes indicate that proteins of this family interact
with protein partners at the depression formed at the center
of the WD-40  -propeller structure. These interactions can
then form an anchor for assembly of larger protein com-
plexes. Such interactions were ﬁrst structurally characterized
for heterotrimeric G-proteins where the  -subunit is a WD-
40 protein (67, 68). Interestingly, interactions between CstF-
50 and the BARD1 linker could rigidify and thereby control
architectural placement of the BARD1 C-terminal region,
thereby reducing the relative ﬂexibility of the ankyrin and
BRCT domains and facilitating interactions with other
factors, as seen for the Rad51 polymerization domain
interaction with BRCA2 (69).
CstF-50 is implicated in the direct recognition of the
C-terminal domain (CTD) of RNA polymerase II, potentially
providing a critical interaction to recruit the CstF complex
to the transcribing RNA polymerase holoenzyme (33, 70, 71).
This interaction does not require the WD-40 domain of CstF-
50 but relies on an N-terminal region that we have shown is
not required for interactions with BARD1 (70). Signiﬁcantly,
since the minimal binding regions do not overlap, the RNAP
II CTD, CstF-50, and the BARD1 C-terminal domains could
potentially all interact within the elongating transcriptional
complex. The proximity of the BARD1 BRCT to the CTD
would allow for additional interactions between the phos-
phorylated CTD and the BARD1 BRCT. Since the BARD1
BRCT preferentially binds phosphopeptides with negatively
charged side chains at the +2 and +3 positions in Vitro (23),
CTD binding by the BARD1 BRCT might be facilitated by
phosphorylation at both the position 2 and 5 serines of the
CTD.
Besides interactions with CstF-50, the BARD1 C-terminal
region is implicated in interactions with p53. These interac-
tions lead to the phosphorylation and stabilization of p53
and are furthermore implicated in facilitating apoptosis in
response to DNA damage (72-74). The ankyrin repeats,
linker, and a portion of the N-terminal BRCT repeat contain
the minimal region of BARD1 required for p53 interactions
(73). The Q564H BARD1 mutation attenuates BARD1-
dependent induction of apoptosis, p53 stabilization, and
interactions with p53, suggesting that the BARD1 linker
region is critical for a functional interaction of BARD1 with
p53 (74). Thus, the C-terminal region of BARD1 can interact
with diverse partner proteins to regulate different aspects of
the DNA damage response. Such proteins that act as hubs
in integrating DNA repair responses are potential master keys
to understanding and eventual therapeutic interventions for
cancer, highlighting the value of understanding the detailed
structural biochemistry underlying pathway control by
multiple structural interactions (75). For BARD1, the struc-
tural plasticity of this region, imparted by the ANK-BRCT
linker, is likely key to the regulated assembly of different
protein complexes with distinct functions in DNA damage
signaling.
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